|
1
|
Yin L, Duan JJ, Bian XW and Yu SC:
Triple-negative breast cancer molecular subtyping and treatment
progress. Breast Cancer Res. 22(61)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wolff AC, Somerfield MR, Dowsett M,
Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA and
Allison KH: Human epidermal growth factor receptor 2 testing in
breast cancer: ASCO-college of american pathologists guideline
update. J Clin Oncol. 41:3867–3872. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bouzid RS, Bouzid R, Labed H, Serhani I,
Hellal D, Oumeddour L, Boudhiaf I, Ibrir M, Khadraoui H and
Belaaloui G: Molecular subtyping and target identification in
triple negative breast cancer through immunohistochemistry
biomarkers. BMC Cancer. 25(454)2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wu Q, Siddharth S and Sharma D: Triple
negative breast cancer: A mountain yet to be scaled despite the
triumphs. Cancers (Basel). 13(3697)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Xiong N, Wu H and Yu Z: Advancements and
challenges in triple-negative breast cancer: A comprehensive review
of therapeutic and diagnostic strategies. Front Oncol.
14(1405491)2024.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lehmann BD, Jovanović B, Chen X, Estrada
MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA:
Refinement of triple-negative breast cancer molecular subtypes:
Implications for neoadjuvant chemotherapy selection. PLoS One.
11(e0157368)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Obidiro O, Battogtokh G and Akala EO:
Triple negative breast cancer treatment options and limitations:
Future outlook. Pharmaceutics. 15(1796)2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen Z, Liu Y, Lyu M, Chan CH, Sun M, Yang
X, Qiao S, Chen Z, Yu S, Ren M, et al: Classifications of
triple-negative breast cancer: Insights and current therapeutic
approaches. Cell Biosci. 15(13)2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li Y, Zhang H, Merkher Y, Chen L, Liu N,
Leonov S and Chen Y: Recent advances in therapeutic strategies for
triple-negative breast cancer. J Hematol Oncol.
15(121)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kumar H, Gupta NV, Jain R, Madhunapantula
SV, Babu CS, Kesharwani SS, Dey S and Jain V: A review of
biological targets and therapeutic approaches in the management of
triple-negative breast cancer. J Adv Res. 54:271–292.
2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tsuchikama K, Anami Y, Ha SYY and Yamazaki
CM: Exploring the next generation of antibody-drug conjugates. Nat
Rev Clin Oncol. 21:203–223. 2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Seo M, Lee J and Ueno NT: Understanding
and overcoming antibody-drug conjugate resistance: Biological
mechanisms and emerging analytical frameworks in breast cancer. Adv
Sci (Weinh). 13(e15498)2026.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nagayama A, Vidula N, Ellisen L and Bardia
A: Novel antibody-drug conjugates for triple negative breast
cancer. Ther Adv Med Oncol. 12(1758835920915980)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Khosravifarsani M, Njotu FN, Fon DA and
Fonge H: Maximizing therapeutic potential and safety: Exploring
multi/dual-payload antibody conjugates as cancer theranostics. Adv
Drug Deliv Rev. 222(115608)2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yang J and Bae H: Drug conjugates for
targeting regulatory T cells in the tumor microenvironment: Guided
missiles for cancer treatment. Exp Mol Med. 55:1996–2004.
2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tsuchikama K and An Z: Antibody-drug
conjugates: Recent advances in conjugation and linker chemistries.
Protein Cell. 9:33–46. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Loganzo F, Sung M and Gerber HP:
Mechanisms of resistance to antibody-drug conjugates. Mol Cancer
Ther. 15:2825–2834. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Aggarwal D, Yang J, Salam MA, Sengupta S,
Al-Amin MY, Mustafa S, Khan MA, Huang X and Pawar JS: Antibody-drug
conjugates: The paradigm shifts in the targeted cancer therapy.
Front Immunol. 14(1203073)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS,
Li ZR and Miao QF: Excellent effects and possible mechanisms of
action of a new antibody-drug conjugate against EGFR-positive
triple-negative breast cancer. Mil Med Res. 8(63)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li T, Zhang T, Dang Y, Lin Y, Li X and
Ling X: Trop2-based antibody-drug conjugates: Emerging strategy and
progress in triple-negative breast cancer therapy Curr. Oncol.
33(92)2026.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fu Z, Li S, Han S, Shi C and Zhang Y:
Antibody drug conjugate: The ‘biological missile’ for targeted
cancer therapy. Signal Transduct Target Ther. 7(93)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G,
Hou P, Cui Q, Xu Z, Wang W, et al: Antibody-Drug Conjugates (ADCs):
Current and future biopharmaceuticals. J Hematol Oncol.
18(51)2025.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Beishenaliev A, Loke YL, Goh SJ, Geo HN,
Mugila M, Misran M, Chung LY, Kiew LV, Roffler S and Teo YY:
Bispecific antibodies for targeted delivery of anti-cancer
therapeutic agents: A review. J Control Release. 359:268–286.
2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gu Y, Wang Z and Wang Y: Bispecific
antibody drug conjugates: Making 1+1>2. Acta Pharm Sin B.
14:1965–1986. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Long R, Zuo H, Tang G, Zhang C, Yue X,
Yang J, Luo X, Deng Y, Qiu J, Li J and Zuo J: Antibody-drug
conjugates in cancer therapy: Applications and future advances.
Front Immunol. 16(1516419)2025.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tao J, Gu Y, Zhou W and Wang Y:
Dual-payload antibody-drug conjugates: Taking a dual shot. Eur J
Med Chem. 281(116995)2025.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mihaylova R, Momekova D, Elincheva V and
Momekov G: Immunoconjugates as an efficient platform for drug
delivery: A resurgence of natural products in targeted antitumor
therapy. Pharmaceuticals (Basel). 17(1701)2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sheyi R, de la Torre BG and Albericio F:
Linkers: An assurance for controlled delivery of antibody-drug
conjugate. Pharmaceutics. 14(396)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Anami Y, Xiong W, Gui X, Deng M, Zhang CC,
Zhang N, An Z and Tsuchikama K: Enzymatic conjugation using
branched linkers for constructing homogeneous antibody-drug
conjugates with high potency. Org Biomol Chem. 15:5635–5642.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Su D and Zhang D: Linker design impacts
antibody-drug conjugate pharmacokinetics and efficacy via
modulating the stability and payload release efficiency. Front
Pharmacol. 12(687926)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Han TH and Zhao B: Absorption,
distribution, metabolism, and excretion considerations for the
development of antibody-drug conjugates. Drug Metab Dispos.
42:1914–1920. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tang SC, Wynn C, Le T, McCandless M, Zhang
Y, Patel R, Maihle N and Hillegass W: Influence of antibody-drug
conjugate cleavability, drug-to-antibody ratio, and free payload
concentration on systemic toxicities: A systematic review and
meta-analysis. Cancer Metastasis Rev. 44(18)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bargh JD, Walsh SJ, Isidro-Llobet A,
Omarjee S, Carroll JS and Spring DR: Sulfatase-cleavable linkers
for antibody-drug conjugates. Chem Sci. 11:2375–2380.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wen M, Yu A, Park Y, Calarese D, Gerber HP
and Yin G: Homogeneous antibody-drug conjugates with dual payloads:
Potential, methods and considerations. MAbs.
17(2498162)2025.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ochtrop P, Jahzerah J, Machui P, Mai I,
Schumacher D, Helma J, Kasper MA and Hackenberger CPR: Compact
hydrophilic electrophiles enable highly efficacious high DAR ADCs
with excellent in vivo PK profile. Chem Sci. 14:2259–2266.
2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gupta N, Kancharla J, Kaushik S, Ansari A,
Hossain S, Goyal R, Pandey M, Sivaccumar J, Hussain S, Sarkar A, et
al: Development of a facile antibody-drug conjugate platform for
increased stability and homogeneity. Chem Sci. 8:2387–2395.
2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Tang Y, Tang F, Yang Y, Zhao L, Zhou H,
Dong J and Huang W: Real-time analysis on drug-antibody ratio of
antibody-drug conjugates for synthesis, process optimization, and
quality control. Sci Rep. 7(7763)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S,
Zhou X and Li S: Antibody-drug conjugates: Recent advances in
linker chemistry. Acta Pharm Sin B. 11:3889–3907. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Balamkundu S and Liu CF:
Lysosomal-cleavable peptide linkers in antibody-drug conjugates.
Biomedicines. 11(3080)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Deng Z and Leng F: A T5 exonuclease-based
assay for DNA topoisomerases and DNA intercalators. ACS Omega.
6:12205–12212. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Mollaei M, Hassan ZM, Khorshidi F and
Langroudi L: Chemotherapeutic drugs: Cell death- and
resistance-related signaling pathways. Are they really as smart as
the tumor cells? Transl Oncol. 14(101056)2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wang Y, Zhang H, Liu C, Wang Z, Wu W,
Zhang N, Zhang L, Hu J, Luo P, Zhang J, et al: Immune checkpoint
modulators in cancer immunotherapy: Recent advances and emerging
concepts. J Hematol Oncol. 15(111)2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yang S, Wei W and Zhao Q: B7-H3, a
checkpoint molecule, as a target for cancer immunotherapy. Int J
Biol Sci. 16:1767–1773. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Loo D, Alderson R, Chen F, Huang L, Zhang
W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, et al:
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with
potent antitumor activity. Clin Cancer Res. 18:3834–3845.
2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhou ZZ, Si Y, Zhang J, Chen K, George A,
Kim S, Zhou L and Liu XM: A dual-payload antibody-drug conjugate
targeting CD276/B7-H3 elicits cytotoxicity and immune activation in
triple-negative breast cancer. Cancer Res. 84:3848–3863.
2024.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Staudacher AH and Brown MP: Antibody drug
conjugates and bystander killing: Is antigen-dependent
internalisation required? Br J Cancer. 117:1736–1742.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Guo Y, Shen Z, Zhao W, Lu J, Song Y, Shen
L, Lu Y, Wu M, Shi Q, Zhuang W, et al: Rational identification of
novel antibody-drug conjugate with high bystander killing effect
against heterogeneous tumors. Adv Sci (Weinh).
11(e2306309)2024.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Nguyen TD, Bordeau BM and Balthasar JP:
Mechanisms of ADC toxicity and strategies to increase ADC
tolerability. Cancers (Basel). 15(713)2023.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Cruz VL, Duro-Sánchez J, Franco-Mateos E,
García-Estévez L, Pérez-García J, Gion M, Garrigós L, Cortez P,
Saavedra C, Gómez P, et al: In silico decrypting of the bystander
effect in antibody-drug conjugates for breast cancer therapy. Sci
Rep. 15(28715)2025.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang
T, Jiang H, Liang B, Xing D and Wang J: Targeting Trop2 in solid
tumors: A look into structures and novel epitopes. Front Immunol.
14(1332489)2023.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Yamazaki CM, Yamaguchi A, Anami Y, Xiong
W, Otani Y, Lee J, Ueno NT, Zhang N, An Z and Tsuchikama K:
Antibody-drug conjugates with dual payloads for combating breast
tumor heterogeneity and drug resistance. Nat Commun.
12(3528)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Liu X, Deng J, Yuan Y, Chen W, Sun W, Wang
Y, Huang H, Liang B, Ming T, Wen J, et al: Advances in
Trop2-targeted therapy: Novel agents and opportunities beyond
breast cancer. Pharmacol Ther. 239(108296)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Kubiatowski T and Kalinka E: Antibody-drug
conjugates in the treatment of advanced triple-negative breast
cancer. Prz Menopauzalny. 24:206–210. 2025.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Sakach E, Sacks R and Kalinsky K: Trop-2
as a therapeutic target in breast cancer. Cancers (Basel).
14(5936)2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wahby S, Fashoyin-Aje L, Osgood CL, Cheng
J, Fiero MH, Zhang L, Tang S, Hamed SS, Song P, Charlab R, et al:
FDA approval summary: Accelerated approval of sacituzumab
govitecan-hziy for third-line treatment of metastatic
triple-negative breast cancer. Clin Cancer Res. 27:1850–1854.
2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Bardia A, Rugo HS, Tolaney SM, Loirat D,
Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy
JO, et al: Final results from the randomized phase III ASCENT
clinical trial in metastatic triple-negative breast cancer and
association of outcomes by human epidermal growth factor receptor 2
and trophoblast cell surface antigen 2 expression. J Clin Oncol.
42:1738–1744. 2024.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Lee HJ and Choi CH: Characterization of
SN38-resistant T47D breast cancer cell sublines overexpressing
BCRP, MRP1, MRP2, MRP3, and MRP4. BMC Cancer.
22(446)2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Yamaguchi A, Hong J, Li L, Kobayashi K,
Yamazaki CM, Ha SYY, Anami Y, Xiong W, Liu J, An Z, et al:
Affinity-optimized TROP2 antibodies support potent antitumor
activity in antibody-drug conjugates. Antib Ther. 9:127–138.
2026.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Cheng Z, Lu X and Feng B: A review of
research progress of antitumor drugs based on tubulin targets.
Transl Cancer Res. 9:4020–4027. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Morcos A, Jung Y, Galvan Bustillos J,
Fuller RN, Caba Molina D, Bertucci A, Boyle KE, Vazquez ME and Wall
NR: A comprehensive review of the antitumor properties and
mechanistic insights of duocarmycin analogs. Cancers (Basel).
16(3293)2024.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Levengood MR, Zhang X, Hunter JH, Emmerton
KK, Miyamoto JB, Lewis TS and Senter PD: Orthogonal cysteine
protection enables homogeneous multi-drug antibody-drug conjugates.
Angew Chem. 129:751–755. 2017.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Rugo HS, Tolaney SM, Loirat D, Punie K,
Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey
LA, et al: Safety analyses from the phase 3 ASCENT trial of
sacituzumab govitecan in metastatic triple-negative breast cancer.
NPJ Breast Cancer. 8(98)2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Dacoregio MI, Michelon I, Ernesto do Rego
Castro C, Cezar Aquino de Moraes F, Rossato de Almeida G, Ravani
LV, Vilbert M and Barros Costa RL: Safety profile of sacituzumab
govitecan in patients with breast cancer: A systematic review and
meta-analysis. Breast. 79(103853)2025.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Ran R, Chen X, Yang J and Xu B:
Immunotherapy in breast cancer: Current landscape and emerging
trends. Exp Hematol Oncol. 14(77)2025.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Chen H, Lu W, Zhou Y, Guo X, Wu S and Chen
Y: Recent advances in antibody-drug conjugates and immunotherapy
combinations for treatment of triple-negative breast cancer. Breast
Cancer (Dove Med Press). 18(571054)2026.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Marchesi S, Marinello A, Ambrosini P,
Cavalli C, Lo Russo G and Occhipinti M: Immune-checkpoint targeting
drug conjugates: A novel class of promising therapeutic agents for
cancer treatment. NPJ Precis Oncol. 9(219)2025.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Ponziani S, Di Vittorio G, Pitari G,
Cimini AM, Ardini M, Gentile R, Iacobelli S, Sala G, Capone E,
Flavell DJ, et al: Antibody-drug conjugates: The new frontier of
chemotherapy. Int J Mol Sci. 21(5510)2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Colak E, Leslie A, Zausmer K, Khatamzas E,
Kubarenko AV, Pichulik T, Klimosch SN, Mayer A, Siggs O, Hector A,
et al: RNA and imidazoquinolines are sensed by distinct TLR7/8
ectodomain sites resulting in functionally disparate signaling
events. J Immunol. 192:5963–5973. 2014.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Picarda E, Ohaegbulam KC and Zang X:
Molecular pathways: Targeting B7-H3 (CD276) for human cancer
immunotherapy. Clin Cancer Res. 22:3425–3431. 2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Zhou Z, Ballard D, Zhang J, Du Z,
Watcharadulyarat N, Varadkar T, Chowdhury S, Kambam SR, Hu P,
Khanal S, et al: Advanced CD276-targeting dual-payload
antibody-drug conjugates for cancer therapy. Cancer Res Commun.
6:898–912. 2026.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Varshney D, Qiu SY, Graf TP and McHugh KJ:
Employing drug delivery strategies to overcome challenges using
TLR7/8 agonists for cancer immunotherapy. AAPS J.
23(90)2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Wilski NA, Haytko P, Zha Z, Wu S, Jin Y,
Chen P, Han C and Chiu ML: A Dual-payload bispecific ADC improved
potency and efficacy over single-payload bispecific ADCs.
Pharmaceutics. 17(967)2025.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Colucci M, Sarill M, Maddalena M, Valdata
A, Troiani M, Massarotti M, Bolis M, Bressan S, Kohl A, Robesti D,
et al: Senescence in cancer. Cancer Cell. 43:1204–1226.
2025.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Herrera M, Pretelli G, Desai J, Garralda
E, Siu LL, Steiner TM and Au L: Bispecific antibodies: Advancing
precision oncology. Trends Cancer. 10:893–919. 2024.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Fan Z: Bispecific antibodies for cancer
therapy: Evolution of structural formats and co-targeting
strategies from wet-lab to AI-driven in silico modeling. Cancer
Let. 653(218578)2026.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Raj S, Kesari KK, Kumar A, Rathi B, Sharma
A, Gupta PK, Jha SK, Jha NK, Slama P, Roychoudhury S and Kumar D:
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in
head and neck cancer. Mol Cancer. 21(31)2022.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Yoshichika R, Mukohara F, Yamada K,
Nagasaki J, Watanabe H, Ueda Y, Suzawa K, Shien K, Toyooka S,
Ishino T and Togashi Y: Immunological effects of amivantamab in
EGFR or MET-expressing non-small cell lung cancer. Cancer Immunol
Immunother. 75(121)2026.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Zhou K, Liu X and Zhu H: Overcoming
resistance to antibody-drug conjugates: From mechanistic insights
to cutting-edge strategies. J Hematol Oncol. 18(96)2025.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Duhon AA and McLean K: Navigating solid
tumor heterogeneity: The promise and challenges of antibody-drug
conjugates. Cancer Heterog Plast. 2:10.47248/chp2502040017.
2025.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Noriega HA and Wang XS: AI-driven
innovation in antibody-drug conjugate design. Front Drug Discov.
5(1628789)2025.
|
|
81
|
Lu Y, Huang W, Li Y, Xu Y, Wei Q, Sha C
and Guo P: Leveraging artificial intelligence in antibody-drug
conjugate development: From target identification to clinical
translation in oncology. NPJ Precis Oncol. 9(374)2025.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Pan J, Yuan X, Yu H, Liu Z, Chen S, Zhu F,
Shang Y, Hong S, Han X, Zhu Z, et al: Igniting cold tumors:
Reprogramming the tumor immune microenvironment with dual-payload
ADCs in combination with PD-L1&4-1BB bispecific antibodies. J
Immunother Cancer. 14(e014392)2026.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Zhao Y, Li Y, Wu F, Qi L, Lei G, Li Y, Xu
Y and Ke X: Abstract LB333: Synergistic antitumor efficacy and
clinical translation of a novel dual-payload TROP2 ADC KH815 in
combination with a PD-L1/VEGF bispecific antibody. Cancer Res. 86
(Suppl 8)(LB333)2026.
|
|
84
|
Attinger-Toller I, Probst P, Bertrand R,
Fay R, Kallenberger L, Maurhofer P, Stark R, Renard E, Santimaria
R, Grabulovski D, et al: Abstract 7334: Targeting nectin-4 with a
first-in-class triple MMAE/dual TOP1i payload ADC showing
synergistic and durable activity across all target expression
levels and favorable tolerability. Cancer Res. 85 (Suppl
8)(S7334)2025.
|
|
85
|
Richardson GE, Kichenadasse G, Zorko N,
Wee Ma W, Chen H, Starks D, Sutherland S, Kamasani S, Khot A, Ma X,
et al: A phase 1/2, first-in-human, open-label, dose-escalation
study of TAK-280, an investigational B7-H3 x CD3ε conditional
bispecific redirected activation (COBRA) T-cell engager, in adult
patients with unresectable, locally advanced, or metastatic solid
tumors. J Clin Oncol. 42(TPS2684)2024.
|
|
86
|
Grairi M and Le Borgne M: Antibody-drug
conjugates: Prospects for the next generation. Drug Discov Today.
29(104241)2024.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Ravenstijn P, Kakinuma T, Hamed S,
Kadokura T, Okada Y and Poondru S: Clinical pharmacology and
translational science considerations in the development of
dual-payload antibody drug conjugates. Clin Transl Sci.
19(e70569)2026.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Liu X, Ma L, Li J, Sun L, Yang Y, Liu T,
Xing D, Yan S and Zhang M: Trop2-targeted therapies in solid
tumors: Advances and future directions. Theranostics. 14:3674–3692.
2024.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Ma F, Wang J, Zhao Y, Song L, Ren P, Qi L,
Qin T, Wu F and Ke X: 653eTiP Translational study and
first-in-human (FIH) study design of KH815, a novel dual-payload
TROP-2 targeted antibody-drug conjugate (ADC), in patients with
advanced solid tumors. Ann Oncol. 36 (Suppl 2)(S451)2025.
|
